New England Journal of Medicine

Journal Information
ISSN / EISSN : 0028-4793 / 1533-4406
Published by: Massachusetts Medical Society (10.1056)
Total articles ≅ 189,717
Current Coverage
SCOPUS
LOCKSS
MEDICUS
MEDLINE
PUBMED
SCIE
Archived in
EBSCO
SHERPA/ROMEO
Filter:

Latest articles in this journal

Published: 29 September 2022
The New England Journal of Medicine, Volume 387, pp 1243-1244; https://doi.org/10.1056/nejmc2211270

Abstract:
To the Editor: It has often seemed that U.S. children’s hospitals were being left out of the value-based care movement. Children’s hospitals don’t have national benchmark quality data from the Centers for Medicare and Medicaid Services (CMS) because they have few Medicare patients, and pediatric patients are not targeted in value-based payment programs from either CMS or commercial payers. Most national comparative-quality systems are not pertinent to pediatric health systems. But as Rosenbaum points out in her series on quality improvement (April 28, May 5, and May 12 issues),1-3 movement toward value-based payment models has shifted the focus from actual . . .
Sham Mailankody, Sean M. Devlin, Jonathan Landa, Karthik Nath, Claudia Diamonte, Elizabeth J. Carstens, Douglas Russo, Romany Auclair, Lisa Fitzgerald, Briana Cadzin, et al.
Published: 29 September 2022
The New England Journal of Medicine, Volume 387, pp 1196-1206; https://doi.org/10.1056/nejmoa2209900

Abstract:
B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapies have generated responses in patients with advanced myeloma, but relapses are common. G protein–coupled receptor, class C, group 5, member D (GPRC5D) has been identified as an immunotherapeutic target in multiple myeloma. Preclinical studies have shown the efficacy of GPRC5D-targeted CAR T cells, including activity in a BCMA antigen escape model.
Published: 29 September 2022
The New England Journal of Medicine, Volume 387, pp 1228-1229; https://doi.org/10.1056/nejme2210686

Abstract:
In January 1922, the management of type 1 diabetes was forever altered when Leonard Thompson became the first person to receive an injection of insulin extract.1 Although treatment with insulin therapy has been possible for more than a century, providers and persons with type 1 diabetes are faced with the grim reality that the attainment of glycemic targets remains elusive for many, increasing the risk of microvascular and macrovascular complications.2 To aid with diabetes management, various technologies have been developed. Some are aimed at measuring glucose, with continuous glucose monitors that currently offer a plethora of data on which to . . .
Eric J. Rubin, Lindsey R. Baden, Stephen Morrissey
Published: 29 September 2022
The New England Journal of Medicine, Volume 387; https://doi.org/10.1056/nejme2212736

Abstract:
The continuing spread of SARS-CoV-2 remains a Public Health Emergency of International Concern. What physicians need to know about transmission, diagnosis, and treatment of Covid-19 is the subject of ongoing updates from infectious disease experts at the Journal.
Shekhar Neema, Santosh Battula
Published: 29 September 2022
The New England Journal of Medicine, Volume 387, pp 1217-1217; https://doi.org/10.1056/nejmicm2202533

Abstract:
A 40-year-old man presented with painless swelling of his earlobes. On examination, painless, indurated nodules of the helixes of both ears and thickening of the greater auricular nerves were observed.
, Matthew Heeney, Terry Jackson, Dan Longo, Melesa Love, Trinity Love, Phillip Okwo, Alexis Thompson, Cassandra Trimnell, Teonna Woolford
Published: 29 September 2022
The New England Journal of Medicine, Volume 387; https://doi.org/10.1056/nejmp2212269

Abstract:
In this short documentary video from the New England Journal of Medicine, patients and physicians partner both to highlight the experience of living with sickle cell disease and to discuss the pathophysiology of the disease and new treatment strategies, including gene therapy.
Published: 29 September 2022
The New England Journal of Medicine, Volume 387, pp 1238-1239; https://doi.org/10.1056/nejmc2210539

Abstract:
To the Editor: Jänne et al. (July 14 issue)1 report the results of a phase 2 study of adagrasib involving patients with KRASG12C-mutated non–small-cell lung cancer (NSCLC). In a post hoc evaluation for intracranial response, the authors highlight a confirmed objective response rate of 33.3% among 33 patients. These patients had previously treated, stable central nervous system (CNS) metastases, and 81.8% of the patients had received radiation therapy before adagrasib treatment (59% within 3 months before study entry and 37% at least 6 months before study entry). CNS target lesions were evaluated in only 13 patients, 9 of whom (69%) . . .
Susanna C. Fagerholm
Published: 28 September 2022
The New England Journal of Medicine; https://doi.org/10.1056/nejmcibr2209679

Abstract:
This year’s Lasker Basic Medical Research Award goes to Drs. Hynes, Ruoslahti, and Springer for their discovery and characterization of a major class of adhesion molecules: the integrins.
Mary E. Norton
Published: 28 September 2022
The New England Journal of Medicine; https://doi.org/10.1056/nejmcibr2209405

Abstract:
The 2022 Lasker–DeBakey Clinical Medical Research Award is awarded to Yuk Ming Dennis Lo for identifying fetal DNA in the maternal circulation, a discovery that led to a revolution in prenatal screening.
, William B. Feldman, S. Sean Tu
Published: 24 September 2022
The New England Journal of Medicine; https://doi.org/10.1056/nejmp2208613

Abstract:
Product hops to albuterol inhalers containing hydrofluoroalkane rather than chlorofluorocarbons cost payers and patients billions of dollars. Without patent and regulatory reform, this pattern is likely to be repeated.
Back to Top Top